JCOG1109-(NEXT)

jRCTs031180202 📎

Regimen

Experimental
neoadjuvant DCF (docetaxel + cisplatin + 5-FU) x3; or neoadjuvant CF + 41.4 Gy RT
Control
neoadjuvant CF (cisplatin + 5-FU) x2

Population

Untreated locally advanced oesophageal squamous cell carcinoma (OSCC), age 20-75, ECOG 0-1

Key finding

3y OS NeoCF+D 72.1% vs NeoCF 62.6% (HR 0.68, P=0.006); NeoCF+RT 68.3% (HR 0.84, NS). Triplet DCF wins; adding RT to CF did NOT improve OS.

Source: PMID 38876133

Timeline

    Guideline citations

    • NCCN ESOPHAGEAL (p.47)